Get In Touch

Depression Drugs Market to Reach Valuation of ~US$ 24.3 Bn by 2030: Transparency Market Research

Depression Drugs Market: Introduction

According to the report, the global depression drugs market was valued at US$ 18.9 Bn in 2019 and is projected to expand at a CAGR of ~2% from 2020 to 2030. Major depressive disorder (MDD), schizophrenia and bipolar I disorder, Obsessive-Compulsive Disorders (OCD), and anxiety disorder are some of the different types of depression. Various drug classes are used to treat depression. These include Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), atypical antidepressants, and tricyclic antidepressants. Rise in prevalence of depression and increase in incidence of depression among the geriatric population is boosting the global depression drugs.

North America dominated the global depression drugs market in 2019. This trend is anticipated to continue during the forecast period. Growth in awareness about the availability of new drugs to treat depression and presence of major companies in the region are expected to drive the depression drugs market in North America. Asia Pacific is likely to be a highly lucrative region of the global depression drugs market during the forecast period.

Rise in Prevalence of Depression and Increase in Geriatric Population to Drive Market

MDD is a commonly diagnosed form of depression. In 2015, around 16.1 million adults aged 18 years and above in the U.S. experienced at least one major depression episode. This represented 6.7% of all adults in the country. Depression is the leading cause of disability among people aged between 15 and 44 in the U.S. More than 41,000 suicides are committed every year in the U.S. Depression is one of the most common illnesses among the elderly population. In addition to the common risk factors prevalent among all age groups, chronic diseases, restricted mobility, bereavement, abuse, isolation, and loss of income are the major risk factors for depression among the geriatric population. The prevalence of depression among adults aged 65 and older is estimated to be between 5% and 10%. Depression is projected to be the second leading cause of disease burden in this age group by 2020.

Atypical Antidepressants Drug Class to Dominate Market

Based on drug class, the global depression drugs market has been divided into Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and  Norepinephrine Reuptake Inhibitors (SNRIs), atypical antidepressants, tricyclic antidepressants,  and others. The atypical antidepressants segment dominated the global depression drugs market in 2019. This trend is projected to continue during the forecast period, as it is first-line of treatment, and due to increase in cases of depression and launch of new drugs.

Schizophrenia and Bipolar I Disorder to be Promising Disease Type

In terms of disease type, the global depression drugs market has been classified into Major Depressive Disorder (MDD), schizophrenia and  bipolar I disorder, Obsessive-Compulsive Disorders (OCD), anxiety disorder, and others. The schizophrenia and  bipolar I disorder segment is expected to expand at the highest CAGR during the forecast period. Rise in cases of schizophrenia and bipolar I disorder and increase in research on the treatment of this disorder are driving the segment. The World Health Organization considers bipolar disorder to be the sixth-largest cause of disability across the globe. According to the WHO data published in October 2019, 20 million people across the globe have been affected with schizophrenia.

Retail Pharmacies Segment Accounted for Major Share of Global Market

Based on distribution channel, the global depression drugs market has been categorized into retail pharmacies, hospital pharmacies, and online pharmacies. The retail pharmacies segment led the global depression drugs market in terms of revenue in 2019. This trend is anticipated to continue during the forecast period. Increase in number of depression drugs being dispensed through retail pharmacies and rise in number of retail pharmacies in developing countries make these a major channel of distribution.

North America to Lead Global Market

The global depression drugs market has been split into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global depression drugs market in 2019. It was followed by Europe. The introduction of new drugs to treat depression and high prevalence of mental illness in developed countries such as the U.S. drive the depression drugs market in North America. The depression drugs market in Asia Pacific is anticipated to expand at a higher CAGR compared to that in other regions from 2020 to 2030. Growth of the depression drugs market in Asia Pacific can be ascribed to rise in prevalence of depression disorders and increase in awareness about the treatment of depression in the region.

Competition Landscape

The global depression drugs market is fragmented in terms of number of players. Key players operating in the global depression drugs market include Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd, Allergan, Novartis AG, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Abbott, Pfizer, and GlaxoSmithKline. New product development through robust R&D activities and mergers & acquisitions are the key strategies adopted by these players in the global depression drugs market.

Depression Drugs Market: Segmentation

  • Depression Drugs Market, by Drug Class
    • Selective Serotonin Reuptake Inhibitors (SSRIs)
    • Serotonin and  Norepinephrine Reuptake Inhibitors (SNRIs)
    • Atypical Antidepressants
    • Tricyclic Antidepressants
    • Others (CNS stimulants, monoamine oxidase inhibitors, etc.)
  • Depression Drugs Market, by Disease Type
    • Major Depressive Disorder
    • Schizophrenia and  Bipolar I Disorder
    • Obsessive-Compulsive Disorders (OCD)
    • Anxiety Disorder
    • Others (ADHD, SSRI-induced disorder, etc.)
  • Depression Drugs Market, by Distribution Channel
    • Retail Pharmacies
    • Hospital Pharmacies
    • Online Pharmacies
  • Depression Drugs Market, by Region
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia Pacific          
      • China
      • India
      • Japan
      • Australia & New Zealand
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East & Africa
      • GCC Countries
      • South Africa
      • Israel
      • Rest of Middle East & Africa

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants, uses proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

7 of 10 large enterprizes view our ToC to take the right decision.

View Report ToC